NASDAQ:TSHA Taysha Gene Therapies (TSHA) Stock Price, News & Analysis → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free TSHA Stock Alerts $2.46 +0.19 (+8.37%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$2.19▼$2.4750-Day Range$1.46▼$3.2552-Week Range$0.50▼$3.89Volume1.46 million shsAverage Volume2.64 million shsMarket Capitalization$460.07 millionP/E RatioN/ADividend YieldN/APrice Target$6.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Taysha Gene Therapies alerts: Email Address Taysha Gene Therapies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside179.5% Upside$6.88 Price TargetShort InterestBearish9.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.39) to ($0.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.30 out of 5 starsMedical Sector502nd out of 909 stocksBiological Products, Except Diagnostic Industry78th out of 154 stocks 4.5 Analyst's Opinion Consensus RatingTaysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTaysha Gene Therapies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.08% of the outstanding shares of Taysha Gene Therapies have been sold short.Short Interest Ratio / Days to CoverTaysha Gene Therapies has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Taysha Gene Therapies has recently increased by 7.46%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTaysha Gene Therapies does not currently pay a dividend.Dividend GrowthTaysha Gene Therapies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TSHA. Previous Next 2.6 News and Social Media Coverage News SentimentTaysha Gene Therapies has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Taysha Gene Therapies this week, compared to 2 articles on an average week.Search InterestOnly 12 people have searched for TSHA on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Taysha Gene Therapies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.25% of the stock of Taysha Gene Therapies is held by insiders.Percentage Held by Institutions77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.39) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Taysha Gene Therapies is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Taysha Gene Therapies is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTaysha Gene Therapies has a P/B Ratio of 6.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingDon’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Taysha Gene Therapies Stock (NASDAQ:TSHA)Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.Read More TSHA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TSHA Stock News HeadlinesApril 20, 2024 | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from AnalystsApril 20, 2024 | americanbankingnews.comCantor Fitzgerald Reiterates "Overweight" Rating for Taysha Gene Therapies (NASDAQ:TSHA)April 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 15, 2024 | finance.yahoo.comCertain Biotech Investors Get an Early Look at Results. Is That Fair?April 14, 2024 | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Down 7.5% April 13, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)April 11, 2024 | markets.businessinsider.comImpact and Outlook: Taysha Gene Therapies Stock AnalysisApril 9, 2024 | msn.comTaysha draws bullish view at Piper Sandler on lead assetApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 9, 2024 | markets.businessinsider.comBuy Rating on Taysha Gene Therapies with TSHA-102 Poised to Transform Rett Syndrome Treatment and Drive Revenue GrowthApril 9, 2024 | markets.businessinsider.comEvaluating Taysha Gene Therapies: Insights From 7 Financial AnalystsApril 5, 2024 | globenewswire.comTaysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 21, 2024 | seekingalpha.comTaysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | markets.businessinsider.comBuy Rating on Taysha Gene Therapies Anchored by Promising TSHA-102 Clinical Data and Upcoming Pediatric Study CatalystsMarch 21, 2024 | finance.yahoo.comTaysha Gene Therapies Full Year 2023 Earnings: Beats ExpectationsMarch 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Taysha Gene Therapies Amid Positive Clinical Progress and Robust Financial HealthMarch 20, 2024 | msn.comTaysha Gene Therapies Shares Jump On Initial Data From First Pediatric Patient With Rare Neurodevelopmental DisorderMarch 20, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Taysha Gene Therapies Amid Clinical Progress and Financial StabilityMarch 20, 2024 | msn.comWhy Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving PremarketMarch 20, 2024 | msn.comTaysha Gene Therapies jumps after early data for Rett syndrome candidateMarch 20, 2024 | finance.yahoo.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | marketwatch.comTaysha Gene Therapies Shares Rise 32% After Data on Rett Syndrome TreatmentMarch 19, 2024 | investorplace.comTSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q4 2023March 19, 2024 | seekingalpha.comTaysha Gene Therapies, Inc. 2023 Q4 - Results - Earnings Call PresentationMarch 19, 2024 | benzinga.comTaysha Gene Therapies: Q4 Earnings InsightsMarch 19, 2024 | benzinga.comTaysha Gene Therapies Stock Soars On FY23 Results: Here's WhyMarch 19, 2024 | globenewswire.comTaysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical UpdatesSee More Headlines Receive TSHA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today4/23/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TSHA CUSIPN/A CIK1806310 Webwww.tayshagtx.com Phone214-612-0000FaxN/AEmployees52Year Founded2020Price Target and Rating Average Stock Price Target$6.88 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+179.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,570,000.00 Net Margins-722.06% Pretax Margin-722.06% Return on EquityN/A Return on Assets-55.72% Debt Debt-to-Equity Ratio0.54 Current Ratio4.08 Quick Ratio4.08 Sales & Book Value Annual Sales$15.45 million Price / Sales29.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.40 per share Price / Book6.15Miscellaneous Outstanding Shares187,020,000Free Float182,810,000Market Cap$460.07 million OptionableOptionable Beta0.29 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Sean P. Nolan (Age 56)CEO & Chairman Comp: $674kDr. Sukumar Nagendran M.D. (Age 57)President, Head of Research & Development and Director Comp: $619.1kMr. Kamran Alam CPA (Age 46)M.B.A., CFO & Corporate Secretary Comp: $703.61kHayleigh CollinsDirector & Head of Corporate CommunicationsMs. Tracy M. Porter SPHRChief People OfficerMr. Frederick Porter Ph.D.Chief of Staff & Technical Operations OfficerMs. Emily McGinnis M.P.H.Chief Patient Advocacy & External Affairs OfficerMr. Sean McAuliffeChief Business OfficerDr. Steven Gray Ph.D.Chief Scientific Advisor of UT Southwestern Gene Therapy ProgramBerge Minassian M.D.Chief Medical Advisor of UT Southwestern Gene Therapy ProgramMore ExecutivesKey CompetitorsEditas MedicineNASDAQ:EDITC4 TherapeuticsNASDAQ:CCCCTourmaline BioNASDAQ:TRMLAlectorNASDAQ:ALECExscientiaNASDAQ:EXAIView All CompetitorsInsiders & InstitutionsCannon Global Investment Management LLCBought 24,200 shares on 4/17/2024Ownership: 0.013%Chicago Partners Investment Group LLCBought 23,740 shares on 2/23/2024Ownership: 0.072%Avoro Capital Advisors LLCBought 430,555 shares on 2/14/2024Ownership: 2.330%ADAR1 Capital Management LLCBought 209,000 shares on 2/14/2024Ownership: 0.112%Dynamic Technology Lab Private LtdBought 17,389 shares on 2/9/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions TSHA Stock Analysis - Frequently Asked Questions Should I buy or sell Taysha Gene Therapies stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TSHA shares. View TSHA analyst ratings or view top-rated stocks. What is Taysha Gene Therapies' stock price target for 2024? 8 equities research analysts have issued twelve-month price objectives for Taysha Gene Therapies' stock. Their TSHA share price targets range from $5.00 to $9.00. On average, they expect the company's stock price to reach $6.88 in the next twelve months. This suggests a possible upside of 179.5% from the stock's current price. View analysts price targets for TSHA or view top-rated stocks among Wall Street analysts. How have TSHA shares performed in 2024? Taysha Gene Therapies' stock was trading at $1.77 at the start of the year. Since then, TSHA stock has increased by 39.0% and is now trading at $2.46. View the best growth stocks for 2024 here. When is Taysha Gene Therapies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TSHA earnings forecast. How were Taysha Gene Therapies' earnings last quarter? Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced its quarterly earnings data on Tuesday, March, 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The firm had revenue of $3.60 million for the quarter, compared to analyst estimates of $4.75 million. When did Taysha Gene Therapies IPO? Taysha Gene Therapies (TSHA) raised $125 million in an initial public offering (IPO) on Thursday, September 24th 2020. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager. Who are Taysha Gene Therapies' major shareholders? Taysha Gene Therapies' stock is owned by many different retail and institutional investors. Top institutional investors include Cannon Global Investment Management LLC (0.01%). Insiders that own company stock include John A Stalfort III, Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II, Sean P Nolan, Sukumar Nagendran and Suyash Prasad. View institutional ownership trends. How do I buy shares of Taysha Gene Therapies? Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TSHA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Taysha Gene Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
